Healthcare Industry News: Bard
News Release - September 10, 2007
E-Z-EM Adds EmpowerMR Injector to Amerinet Group Purchasing ContractLAKE SUCCESS, N.Y.--(HSMN NewsFeed)--E-Z-EM, Inc. (NASDAQ:EZEM ) today announced that Amerinet, one of the nation's largest group purchasing organizations, has added the Company's EmpowerMRŽ injector system to the non-exclusive purchasing agreement currently in place for its EmpowerŽ line of CT injector systems. This agreement is the first to include EmpowerMR injectors with a major Group Purchase Organization, and will provide Amerinet's more than 2,100 hospital members access to preferred contract pricing for EmpowerMR injectors. The three-year agreement is effective as of September 15, 2007.
EmpowerMR employs a hydraulic control system instead of the shielded electrical control components used by most other MR injector systems. EmpowerMR has no shielded iron motors, piezoelectric motors or electrically active motor control circuitry adjacent to the scanner, which significantly minimizes the prospect of electrical interference with the scanner's magnetic field. EmpowerMR is also not battery operated, and links to its electrical supply by a single pass-through cable that does not require special shielding. Because there is no motor in the MR suite, EmpowerMR does not generate audible noise. EmpowerMR's hydraulic control also means the system can deliver consistent flow rates, volumetric and pressure performance on demand--features which may help improve productivity in the MR suite.
The Company's Empower product line is the only family of injectors on the market powered by the IRiS(TM) Injector Reporting Information System, a powerful software application that automatically captures operational data from several important functions of the injector. When used to network all injector systems in a facility, IRiS helps consolidate data from the entire Radiology department, facilitating quantitative analysis and simplifying budgeting, while allowing busy administrators to focus on other critical management tasks. EmpowerCT and EmpowerCTA injectors are also available with patented EDA(TM) technology that can help detect contrast extravasation.
Commenting on the release, Anthony A. LomBardo, president and chief executive officer of E-Z-EM, said, "This agreement extends to Amerinet's membership the same opportunity for preferred pricing for our EmpowerMR injector system as they now enjoy for our other award winning Empower products."
About E-Z-EM, Inc.
E-Z-EM is a leading manufacturer of contrast agents for gastrointestinal radiology. The Company is the developer of VoLumenŽ, a low density barium sulfate suspension for use as an oral contrast in Multidetector CT (MDCT) and Positron Emission Tomography (PET/CT) studies. The Company also offers EmpowerŽ--the only family of CT injectors on the market with patented EDA(TM) technology that can help detect contrast extravasation--and offers a complete product set for the virtual colonoscopy practitioner. This product line consists of virtual colonoscopy hardware, software, nutritional prep kits and bowel cleaners, tagging agents and a carbon dioxide colon insufflation system. The Company is also the exclusive world-wide manufacturer and marketer of RSDL for first-responder organizations and military services. RSDL is a patented, broad-spectrum liquid chemical warfare (CW) agent decontaminant, that neutralizes or removes chemical agents from skin on contact, leaving a non-toxic residue that can be rinsed off with water.
The statements made in this document contain certain forward-looking statements. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates" or variations of such words and similar expressions, are intended to identify such forward-looking statements. The forward-looking statements contained in this release may involve numerous risks and uncertainties, known and unknown, beyond the Company's control. Such risks and uncertainties include: the ability of the Company to develop its products; the impact and future sales derived from the Amerinet purchase agreement for Empower products, market acceptance and sales of VoLumenŽ; future actions by the FDA or other regulatory agencies, overall economic conditions, general market conditions, price increases of raw materials and components, foreign currency exchange rate fluctuations as well as the risk factors listed from time to time in the SEC filings of E-Z-EM, Inc., including but not limited to its Annual Report on Form 10-K for the fiscal year ended June 2, 2007. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements, and investors are cautioned not to place undue reliance on the forward-looking statements included in this release.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.